| Home | E-Submission | Sitemap | Contact Us |  
Korean J Med > Volume 94(6); 2019 > Article
The Korean Journal of Medicine 2019;94(6): 485-494.
말단비대증 환자에서 소마토스타틴 유사체 사용에 대한 권고안
진상욱1, 구철룡2, 김병준3, 김성운1, 박경혜4, 송기호5, 오승준1, 윤현구6, 이은직2, 이정민7, 임정수8, 김정희9, 김광준10, 진흥용11, 김대중12, 이경애11, 문성수13, 임동준7, 신동엽2, 김세화14, 권민정15, 김하영16, 김진화17, 김동선18, 김종화19
1경희대학교 의과대학 내분비대사내과학교실
2연세대학교 의과대학 세브란스병원 내분비내과
3가천대학교 길병원 내과
4국민건강보험 일산병원 내분비내과
5건국대학교 의과대학 건국대학교병원 내분비대사내과
6단국대학교 의과대학 제일여성병원 내분비내과
7가톨릭대학교 의과대학 내과학교실
8연세대학교 의과대학 원주세브란스기독병원 내분비대사내과
9서울대학교병원 내분비대사내과
10연세대학교 의과대학 세브란스병원 노년내과
11전북대학교 의과대학 내과학교실
12아주대학교 의과대학 아주대학교병원 내분비대사내과
13동국대학교 경주병원 내분비내과
14가톨릭관동대학교 국제성모병원 내분비내과
15인제대학교 부산백병원 내분비대사내과
16원광대학교 산본병원 내분비내과
17조선대학교병원 내분비대사내과
18한양대학교 의과대학 내분비대사내과학교실
19세종병원 내분비내과
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Sang Ouk Chin1, Cheol Ryong Ku2, Byung Joon Kim3, Sung-Woon Kim1, Kyeong Hye Park4, Kee Ho Song5, Seungjoon Oh1, Hyun Koo Yoon6, Eun Jig Lee2, Jung Min Lee7, Jung Soo Lim8, Jung Hee Kim9, Kwang Joon Kim10, Heung Yong Jin11, Dae Jung Kim12, Kyung Ae Lee11, Seong-Su Moon13, Dong Jun Lim7, Dong Yeob Shin2, Se Hwa Kim14, Min Jeong Kwon15, Ha Young Kim16, Jin Hwa Kim17, Dong Sun Kim18, Chong Hwa Kim19
1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea
2Department of Endocrinology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
4Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
6Department of Endocrinology and Metabolism, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea
7Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
8Department of Endocrinology and Metabolism, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju, Korea
9Department of Endocrinology and Metabolism, Seoul National University Hospital, Seoul, Korea
10Division of Geriatrics, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
11Department of Internal Medicine, Medical School of Chonbuk National University, Jeonju, Korea
12Department of Endocrinology and Metabolism, Ajou Medical Center, Ajou University School of Medicine, Suwon, Korea
13Department of Endocrinology, Dongguk University Gyeongju Hospital, Gyeongju, Korea
14Department of Endocrinology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea
15Department of Endocrinology and Metabolism, Inje University Busan Paik Hospital, Busan, Korea
16Division of Endocrinology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Korea
17Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea
18Department of Endocrinology and Metabolism, Hanyang University College of Medicine, Seoul, Korea
19Department of Endocrinology and Metabolism, Sejong General Hospital, Bucheon, Korea
Corresponding Author: Chong Hwa Kim ,Tel: +82-2-2290-8328, Fax: +82-2-2298-9183, Email: dongsun@hanyang.ac.kr
Received: May 9, 2019;   Accepted: June 27, 2019.
Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.
Keywords: Acromegaly; Somatostatin; Octreotide; Lanreotide; Pasireotide
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community